Martin-Killias, P; Stefan, N; Rothschild, S; Plückthun, A; Zangemeister-Wittke, U (2011). A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clinical Cancer Research, 17(1):100-110.
Stefan, N; Martin-Killias, P; Wyss-Stoeckle, S; Honegger, A; Zangemeister-Wittke, U; Plückthun, A (2011). DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. Journal of Molecular Biology, 413(4):826-43.
Winkler, J; Martin-Killias, P; Plückthun, A; Zangemeister-Wittke, U (2009). EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Molecular Cancer Therapeutics, 8(9):2674-2683.